Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C19H31N5O2.ClH |
| Molecular Weight | 397.943 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CC(C)CC(=O)NC1=NNC2=C1CN(C(=O)C3CCN(C)CC3)C2(C)C
InChI
InChIKey=MZIJMKKRMFWACJ-UHFFFAOYSA-N
InChI=1S/C19H31N5O2.ClH/c1-12(2)10-15(25)20-17-14-11-24(19(3,4)16(14)21-22-17)18(26)13-6-8-23(5)9-7-13;/h12-13H,6-11H2,1-5H3,(H2,20,21,22,25);1H
| Molecular Formula | ClH |
| Molecular Weight | 36.461 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C19H31N5O2 |
| Molecular Weight | 361.4817 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/20167248 | https://www.ncbi.nlm.nih.gov/pubmed/20153204Curator's Comment: Description was created based on several sources, including
Sources: https://www.ncbi.nlm.nih.gov/pubmed/20167248 | https://www.ncbi.nlm.nih.gov/pubmed/20153204
Curator's Comment: Description was created based on several sources, including
PHA-793887 is an inhibitor of multiple cyclin dependent kinases (CDK) with activity against CDK2, CDK1 and CDK4. PHA-793887 was cytotoxic for leukemic cell lines in vitro, with IC(50) ranging from 0.3 to 7 uM. In colony assays PHA-793887 showed very high activity against leukemia cell lines, with an IC(50) <0.1 uM indicating that it has efficient and prolonged antiproliferative activity. PHA-793887 induced cell-cycle arrest, inhibited Rb and nucleophosmin phosphorylation. PHA-793887 has promising therapeutic activity against acute leukemias in vitro and in vivo.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL1907600 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20153204 |
5.0 nM [IC50] | ||
Target ID: CHEMBL2094128 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20153204 |
8.0 nM [IC50] | ||
Target ID: CHEMBL1907605 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20153204 |
8.0 nM [IC50] | ||
Target ID: CHEMBL2111288 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20153204 |
10.0 nM [IC50] | ||
Target ID: CHEMBL1907602 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20153204 |
60.0 nM [IC50] | ||
Target ID: CHEMBL1907601 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20153204 |
62.0 nM [IC50] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Unknown Approved UseUnknown |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
5.807 μM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21368575 |
66 mg/m² 1 times / week multiple, intravenous dose: 66 mg/m² route of administration: Intravenous experiment type: MULTIPLE co-administered: |
PHA-793887 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
3.607 μM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21368575 |
44 mg/m² 1 times / week multiple, intravenous dose: 44 mg/m² route of administration: Intravenous experiment type: MULTIPLE co-administered: |
PHA-793887 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
13.072 μM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21368575 |
66 mg/m² 1 times / week multiple, intravenous dose: 66 mg/m² route of administration: Intravenous experiment type: MULTIPLE co-administered: |
PHA-793887 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
10.148 μM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21368575 |
44 mg/m² 1 times / week multiple, intravenous dose: 44 mg/m² route of administration: Intravenous experiment type: MULTIPLE co-administered: |
PHA-793887 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
7.247 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21368575 |
66 mg/m² 1 times / week multiple, intravenous dose: 66 mg/m² route of administration: Intravenous experiment type: MULTIPLE co-administered: |
PHA-793887 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
9.177 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21368575 |
44 mg/m² 1 times / week multiple, intravenous dose: 44 mg/m² route of administration: Intravenous experiment type: MULTIPLE co-administered: |
PHA-793887 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Transcriptional analysis of an E2F gene signature as a biomarker of activity of the cyclin-dependent kinase inhibitor PHA-793887 in tumor and skin biopsies from a phase I clinical study. | 2010-05 |
|
| Optimization of 6,6-dimethyl pyrrolo[3,4-c]pyrazoles: Identification of PHA-793887, a potent CDK inhibitor suitable for intravenous dosing. | 2010-03-01 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/20167248
Mice: PHA-793887 was administered at 20 mg/kg intravenous (IV) once a day, continuously for 10 days (from day 9 to day 18) in HL60 model and with a two 5-day cycles (from day 9 to day 13 and from day 17 to day 21) in K562-bearing mice.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/20167248
PHA-793887 was cytotoxic for leukemic cell lines in vitro, with IC(50) ranging from 0.3 to 7 uM (mean: 2.9 uM). in colony assays PHA-793887 showed very high activity against leukemia cell lines, with an IC(50) <0.1 uM (mean: 0.08 uM). PHA-793887 induced cell-cycle arrest, inhibited Rb and nucleophosmin phosphorylation, and modulated cyclin E and cdc6 expression at low doses (0.2-1 uM) and induced apoptosis at the highest dose (5 uM).
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 23:29:49 GMT 2025
by
admin
on
Mon Mar 31 23:29:49 GMT 2025
|
| Record UNII |
Z5MR1JR732
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
718630-60-5
Created by
admin on Mon Mar 31 23:29:49 GMT 2025 , Edited by admin on Mon Mar 31 23:29:49 GMT 2025
|
PRIMARY | |||
|
Z5MR1JR732
Created by
admin on Mon Mar 31 23:29:49 GMT 2025 , Edited by admin on Mon Mar 31 23:29:49 GMT 2025
|
PRIMARY | |||
|
72941850
Created by
admin on Mon Mar 31 23:29:49 GMT 2025 , Edited by admin on Mon Mar 31 23:29:49 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
SALT/SOLVATE -> PARENT |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |